Omeros Corp (OMER) Q3 2026 Earnings Call Highlights: YARTEMLEA Sales Surge 30%

Omeros Corp (OMER) reported Q3 2026 earnings with YARTEMLEA sales up 30% QoQ to $41.8M. Net loss widened to $57.4M due to a non-cash mark-to-market loss. Operating cash flow was positive at $13.3M. The company faces delays in Europe and increased gross-to-net deductions. OMER did not provide Q4 or 2027 guidance. Pipeline programs and NTAP benefits were highlighted.

Original reporting
Published Nov 17, 2026, 5:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 5:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Omeros Corp (OMER) Q3 2026 Earnings Call Highlights: YARTEMLEA Sales Surge 30% — source image
Decision brief

The 30-second read

$OMERNeutralMed
01

Why it matters

YARTEMLEA shows strong quarter-over-quarter growth and cash flow positivity, but Europe faces a CHMP negative opinion and management flags no near-term revenue guidance. Gross-to-net pressure is expected to persist into the high-teens range, and pipeline timelines include delays for OMS527.

02

Market read

Traders get a fresh mix of catalysts: strong US commercial momentum and cash flow, offset by Europe regulatory delay and worsening gross-to-net deductions, plus guidance uncertainty.

03

What to watch

The article notes no Q4 2026 or 2027 revenue guidance; traders may overreact to the lack of guidance without separating reimbursement education ramp and NTAP uptake timing.

Relevance 8/10Novelty 6/10Timing: post-earnings call, before Q4 guidance absence becomes a focus

Background

The piece summarizes Omeros’ Q3 2026 earnings call, focusing on YARTEMLEA commercial performance, cash flow, reimbursement mechanics (NTAP, 340B), and pipeline/regulatory updates.

Company-level read

Ticker impact

$OMERNeutralHigh confidence
Context

Omeros reports YARTEMLEA Q3 sales growth, positive operating cash flow, but also a widened GAAP loss and a CHMP negative opinion in Europe.

Expected impact

Likely mixed reaction, with upside from YARTEMLEA momentum offset by downside from CHMP negative opinion and higher gross-to-net deductions.

Evidence & confidence

The article provides specific Q3 commercial metrics, cash flow, and explicit regulatory and pricing headwinds, which directly affect valuation and forward expectations.

Market effects

Reinforces that complement/transplant-focused biotech commercialization can be strong in the US while Europe regulatory outcomes remain a key swing factor.

Europe expansion risk increases due to CHMP negative opinion, while US adoption and reimbursement mechanics remain the primary driver.

Limited direct global macro linkage; the main global read-through is regulatory path dependency for rare-disease therapies.

Counterpoint

Gross-to-net deterioration is largely tied to 340B utilization and may be a transitional effect as care shifts outpatient, not a permanent pricing impairment.

Key entities

  • Omeros Corp

    NASDAQ-listed biotech reporting Q3 2026 earnings call highlights for YARTEMLEA and pipeline/regulatory updates.

  • YARTEMLEA (narsoplimab)

    Omeros’ therapy whose Q3 sales growth and reimbursement dynamics drive the commercial narrative.

  • CHMP

    European committee issuing a negative opinion on the narsoplimab marketing authorization application for TA-TMA.

  • NTAP

    New Technology Add-On Payment program providing up to $287,000 per eligible Medicare inpatient case.

  • 340B

    Program affecting gross-to-net deductions, with management expecting gross-to-net to approach the high-teens.

Related articles

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

$OMERMed

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

$OMERMedAI 8/10

Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.

$OMERMed

Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q